Martin D. Berger

University Name

Research Interests

Explore related searches

Contact this professor

Google Scholar

Articles (29)

Collaborators (16)

Andreas Wicki

University of Zurich

Carlo Largiader

University Hospital of Bern

Giuseppe Masucci

Karolinska Institutet

Christoph Kurmann

University Hospital of Bern

Simon Jung

University Hospital of Bern

Marc Van den Eynde

Associate Professor

Université catholique de Louvain

Inti Zlobec

University of Bern

Vanessa Banz

Yu Sunakawa

St. Marianna University School of Medicine

J. Jack Lee

The University of Texas MD Anderson Cancer Center

UNITED STATES

Francesco Ciompi

Associate Professor

Radboud University Medical Center

Teresa Macarulla

Head of Gastrointestinal and Endocrine Tumor Unit

Hospital Universitari Vall d'Hebron

Luigi Laghi

Associate professor of gastroenterology

University of Parma

Toshihiko Torigoe

Sapporo Medical University

Kristýna Němejcová

Všeobecná Fakultní Nemocnice v Praze

CZECH REPUBLIC

Chiara Cremolini

University Hospital of Pisa

Martin D. Berger

Research Interests

Explore related searches

Contact this professor

Articles (29)

Combining immunoscore and tumor budding in colon cancer: an insightful prognostication based on the tumor-host interface.

Cone Beam Computed Tomography-Based Online Adaptive Radiation Therapy of Esophageal Cancer: First Clinical Experience and Dosimetric Benefits.

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer: A Multicenter Phase Ib Trial (RECAP)-SAKK 41/16.

Cancer and left atrial enlargement in patients with ischemic stroke.

Mortality in acute ischemic stroke patients with new cancer diagnosed during the index hospitalization versus after discharge.

Non-specific presentation of metastatic small bowel adenocarcinoma with diagnostic challenges.

The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition.

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (&lt;i&gt;DPYD&lt;/i&gt;).

Prevalence of right-to-left shunt in stroke patients with cancer.

Multicenter International Study of the Consensus Immunoscore for the Prediction of Relapse and Survival in Early-Stage Colon Cancer

PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system

Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomy.

The complexity of shapes; how the circularity of tumor nodules impacts prognosis in colorectal cancer.

The Role of Immune Checkpoint Inhibitors in Metastatic Pancreatic Cancer: Current State and Outlook.

Transient ischemic attacks in patients with active and occult cancer.

Watchful Waiting after Definitive Radiochemotherapy in Patients with Esophageal Cancer: Independent Predictors for Recurrence

Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related stroke.

Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?-A systematic review.

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.

Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients.

Potential Molecular Cross Talk Among CCR5 Pathway Predicts Regorafenib Responsiveness in Metastatic Colorectal Cancer Patients.

RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.

Refining the ITBCC tumor budding scoring system with a "zero-budding" category in colorectal cancer.

CCR5 is a potential therapeutic target for cancer.

Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer.

Role of enterocyte-specific gene polymorphisms in response to adjuvant treatment for stage III colorectal cancer.

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients.

The impact of ARID1A mutation on molecular characteristics in colorectal cancer.

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer.

Collaborators (16)

Andreas Wicki

Carlo Largiader

Giuseppe Masucci

Christoph Kurmann

Simon Jung

Marc Van den Eynde

Inti Zlobec

Vanessa Banz

Yu Sunakawa

J. Jack Lee

Francesco Ciompi

Teresa Macarulla

Luigi Laghi

Toshihiko Torigoe

Kristýna Němejcová

Chiara Cremolini

How do I reach out?

Meet Kite AI

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (<i>DPYD</i>).